Guggenheim Upgrades Bristol Myers to Buy with $62 Target
Guggenheim raises Bristol Myers to Buy, citing low expectations, strong pipeline, and potential entry point for value-focused investors.
/ 1664 items
#XY↓
Arcus and Gilead Halt Cancer Trial After Treatment Fails to Extend Patient Survival
Arcus Biosciences discontinues Phase 3 STAR-221 cancer trial after independent review finds experimental treatment unlikely to improve survival for gastric and esophageal cancer patients.
Wells Fargo Upgrades Relay Therapeutics and Zymeworks Stocks
Wells Fargo upgrades Relay Therapeutics and Zymeworks, raising price targets and highlighting potential 2026 growth from clinical data and cancer treatment opportunities.
Trump Signals Major Shift on U.S. Cannabis Policy as Pot Stocks Surge
Cannabis stocks jumped after reports that President Trump may push to reclassify marijuana to Schedule III, easing restrictions and boosting industry prospects.
Anixa Reports Positive Phase 1 Breast Cancer Vaccine Data
Anixa Biosciences announced positive Phase 1 data for its investigational breast cancer vaccine, showing strong safety and immune response results in 74% of participants.
Applied Therapeutics Shares Plunge as Cycle Group Announces Deep-Discount Buyout
Applied Therapeutics’ stock drops 33% premarket after Cycle Group agrees to acquire the company at a steep discount, with potential future CVR payouts and a closing expected in early 2026.